Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Cannabis Investors Are Watching Herbal Dispatch (CSE:HERB) (click to learn more) AI Wellness Stock Targeting Massive Growth (CSE: ALEN.U) (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News argenx SE ARGX

Healthcare Biotechnology
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYGART and VYGART HYTRULO to treat generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops... see more

Current News (NDAQ:ARGX)

argenx to Report Full Year 2025 Financial Results and Fourth Quarter Business Update on February 26, 2026

GlobeNewswire 3 hours ago

argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART in AChR-Ab Seronegative gMG

GlobeNewswire January 13, 2026

argenx Highlights 2026 Strategic Priorities

GlobeNewswire January 12, 2026

argenx to Present at 44th Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 6, 2026

argenx Announces Leadership Transition Marking Next Evolution of Growth

GlobeNewswire January 5, 2026

argenx Provides Update on UplighTED Studies of Efgartigimod SC in Thyroid Eye Disease

GlobeNewswire December 15, 2025

argenx Announces Results of Extraordinary General Meeting of Shareholders

GlobeNewswire November 18, 2025

argenx Reports Third Quarter 2025 Financial Results and Provides Business Update

GlobeNewswire October 30, 2025

argenx Presents New Data at AANEM and MGFA Highlighting the Strength and Broad Benefit of VYVGART for Myasthenia Gravis Patients

GlobeNewswire October 29, 2025
View More News ››

Opinion & Analysis (NDAQ:ARGX)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:ARGX)

Great day

Up $7,  lots more room to run.
Joe455 - May 29, 2022
View more Bullboard ››

Freegold Ventures Limited

Freegold Ventures Limited

Freegold Ventures Limited is a Canada-based company focused on exploration in Alaska. The Company holds the Summit Gold ...
View More »

Podcasts